India Market Share
8.2%
+40bps YoY
Sun Pharma gained 40 bps market share in the Indian pharma market (AIOCD AWACS Dec 2024).
SUNPHARMA
Healthcare
13 Feb 2025
Sunpharma Ltd — Q3 FY25
Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth).
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth). EBITDA margin expanded 120 bps YoY to 29.3%, aided by lower material costs and milestone income. Adjusted PAT grew 24.1% YoY to INR 3,220 crore. Specialty sales rose 24.8% to $370M, with balanced contribution from US and ex-US markets. India business gained 40 bps market share to 8.2%, led by volume and new launches. R&D spend was lower than guided at 6.3% of sales due to clinical trial delays; FY25 R&D guidance trimmed to <7%. Management remains focused on specialty pipeline, including Leqselvi (litigation oral arguments in April) and Antibe acquisition. Key risk: potential US tariff policy changes and FDA compliance issues at Halol facility could impact generics recovery.
सन फार्मा की तीसरी तिमाही (अक्टूबर-दिसंबर 2024) की कमाई अच्छी रही। कंपनी की कुल बिक्री 13,437 करोड़ रुपये रही, जो पिछले साल से 10.5% ज्यादा है। भारत में बिक्री 13.8% और उभरते बाजारों में 10.1% बढ़ी। कंपनी का मुनाफा (EBITDA) 29.3% रहा, जो पिछले साल से 1.2% ज्यादा है। इसकी वजह कम कच्चे माल की लागत और माइलस्टोन आय है। शुद्ध मुनाफा (PAT) 24.1% बढ़कर 3,220 करोड़ रुपये हो गया। स्पेशलिटी दवाओं की बिक्री 24.8% बढ़ी। भारत में बाजार हिस्सेदारी 8.2% हो गई। रिसर्च पर खर्च 6.3% रहा, जो अनुमान से कम है। कंपनी ने सालाना रिसर्च खर्च का अनुमान 7% से कम कर दिया है। प्रबंधन नई दवाओं पर ध्यान दे रहा है। जोखिम: अमेरिकी टैरिफ नीति और हलोल फैक्ट्री की एफडीए मंजूरी से जेनरिक दवाओं पर असर पड़ सकता है।
Key Numbers
Global Specialty Sales
$370M
+24.8% YoY
Specialty sales grew strongly, driven by Ilumya, Cequa, Odomzo, and Winlevi.
US Formulation Sales
$474M
-1% YoY
US sales declined slightly due to lower temozolomide sales, offset by specialty growth.
R&D Spend as % of Sales
6.3%
-70bps YoY
R&D spend was lower due to clinical trial delays; FY25 guidance reduced to <7%.
What Changed vs Last Quarter
NEW
Leqselvi launch timeline dependent on litigation outcome
Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.
NEW
Specialty sales growth to normalize after Q3 inventory build
Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.
UPDATED
FY25 R&D spend to be less than 7% of sales
Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.
DROPPED
Leqselvi launch readiness within weeks of favorable judgment
Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation.
DROPPED
Ilumya PsA Phase III data expected H2 CY2025
Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.
NEW RISK
US Tariff and Policy Uncertainty
Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.
NEW RISK
FDA Compliance at Halol Facility
Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.
NEW RISK
Leqselvi Litigation Risk
If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.
NEW RISK
Clinical Trial Delays Impacting R&D Pipeline
Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones.
RISK GONE
Leqselvi patent litigation binary outcome
The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.
RISK GONE
R&D spend may remain below guidance if trials delay further
Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.
RISK GONE
Higher selling expenses pressuring margins
Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.
RISK GONE
Japan price cuts impacting ROW revenues
Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24, Q4 FY24
R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies.
Mentioned in Q1 FY25, Q2 FY24
Tax rate expected to rise due to expiry of certain exemptions; should be viewed on an annualized basis.
Mentioned in Q1 FY24, Q2 FY24
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
Mentioned in Q1 FY24, Q3 FY24
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
Mentioned in Q2 FY24, Q4 FY24
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
Management Guidance
FY25 R&D spend to be less than 7% of sales
Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.
Management guidance otherLeqselvi launch timeline dependent on litigation outcome
Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.
Management guidance otherSpecialty sales growth to normalize after Q3 inventory build
Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.
Management guidance revenueKey Risks
US Tariff and Policy Uncertainty
Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.
medium · analyst_questionFDA Compliance at Halol Facility
Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.
high · management_commentaryLeqselvi Litigation Risk
If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.
high · management_commentaryClinical Trial Delays Impacting R&D Pipeline
Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones.
medium · analyst_questionNotable Quotes
We will remain opportunistic, but the focus on dermatology and ophthalmology will continue.
The growth in specialty, whether looked at quarter-on-quarter, year-on-year, has come from both U.S. and ex-U.S. markets.
We have invited the agency to inspect our Halol, but when to inspect is a decision that they take.
Frequently Asked Questions
What was Sunpharma's revenue in Q3 FY25?
Sunpharma reported revenue of ₹13,437 Cr in Q3 FY25, representing a +10.5% change compared to the same quarter last year.
What guidance did Sunpharma management give for FY26?
FY25 R&D spend to be less than 7% of sales: Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales. Leqselvi launch timeline dependent on litigation outcome: Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026. Specialty sales growth to normalize after Q3 inventory build: Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.
What are the key risks for Sunpharma in FY26?
Key risks include US Tariff and Policy Uncertainty — Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.; FDA Compliance at Halol Facility — Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.; Leqselvi Litigation Risk — If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.; Clinical Trial Delays Impacting R&D Pipeline — Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones..
Did Sunpharma meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Sunpharma Q3 FY25 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.